Literature DB >> 10508586

Binding of Gbetagamma subunits to cRaf1 downregulates G-protein-coupled receptor signalling.

J R Slupsky1, U Quitterer, C K Weber, P Gierschik, M J Lohse, U R Rapp.   

Abstract

Receptors of the seven transmembrane domain family are coupled to heterotrimeric G proteins [1]. Binding of ligand to these receptors induces dissociation of the heterotrimeric complex into free GTP-Galpha and Gbetagamma subunits, which then interact with their respective effector molecules to stimulate specific cellular responses. In some cases, these cellular responses involve mitogenic signalling [2]. The mitogen-activated protein (MAP) kinase cascade is initiated by the protein kinase cRaf1 and links growth factor receptor signalling to cell growth and differentiation [3]. The main activator of cRaf1 is the small GTP-binding protein Ras [4], and the binding of cRaf1 to GTP-Ras translocates cRaf1 to the plasma membrane, where it is activated [5]. It has been reported that cRaf1 associates directly with the beta subunit of heterotrimeric G proteins in vitro, and with the betagamma subunit complex in vivo [6], but the role of this association is not yet understood. Here, we show that cRaf1 associates with Gbeta1gamma2, and that this association in mammalian cells is significantly enhanced when active p21(Ras) is present or when cRaf1 is otherwise targeted to the membrane. Association with Gbeta1gamma2 has no effect on the kinase activity of cRaf1, but cRaf1 can affect Gbetagamma-mediated signalling events. Thus, membrane-localised cRaf1 inhibits G-protein-coupled receptor (GPCR)-stimulated activation of phospholipase Cbeta (PLCbeta) by sequestration of Gbetagamma subunits, an effect also observed with endogenous levels of cRaf1. Our data suggest that cRaf1 may be an important regulator of signalling by Gbetagamma, particularly in those GPCR systems that stimulate the MAP kinase cascade through the activation of p21(Ras).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508586     DOI: 10.1016/s0960-9822(99)80426-6

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  10 in total

Review 1.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

2.  Inhibition of AC-II activity following chronic agonist exposure is modulated by phosphorylation.

Authors:  Ester Schallmach; Debora Steiner; Zvi Vogel
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

3.  IL-13 desensitizes β2-adrenergic receptors in human airway epithelial cells through a 15-lipoxygenase/G protein receptor kinase 2 mechanism.

Authors:  Giusy D Albano; Jinming Zhao; Emily B Etling; Seo Young Park; Haizhen Hu; John B Trudeau; Mirella Profita; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2015-03-24       Impact factor: 10.793

Review 4.  Role of Raf kinase inhibitor protein in Helicobacter pylori-mediated signaling in gastric cancer.

Authors:  Liana Nisimova; Sicheng Wen; Sam Cross-Knorr; Arlin B Rogers; Steven F Moss; Devasis Chatterjee
Journal:  Crit Rev Oncog       Date:  2014

5.  Carboxyl terminus-truncated α1D-adrenoceptors inhibit the ERK pathway.

Authors:  Marco A Alfonzo-Méndez; Jean A Castillo-Badillo; M Teresa Romero-Ávila; Richard Rivera; Jerold Chun; J Adolfo García-Sáinz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-05       Impact factor: 3.000

6.  A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy.

Authors:  Kristina Lorenz; Joachim P Schmitt; Eva M Schmitteckert; Martin J Lohse
Journal:  Nat Med       Date:  2008-12-07       Impact factor: 53.440

7.  Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas.

Authors:  Rachel Kim; Alla Trubetskoy; Takeshi Suzuki; Nancy A Jenkins; Neal G Copeland; Jack Lenz
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 8.  Signaling to cardiac hypertrophy: insights from human and mouse RASopathies.

Authors:  Valentina Sala; Simona Gallo; Christian Leo; Stefano Gatti; Bruce D Gelb; Tiziana Crepaldi
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

9.  Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer.

Authors:  Saad Yousuf; MeiLi Duan; Erika L Moen; Sam Cross-Knorr; Kate Brilliant; Benjamin Bonavida; Theresa LaValle; Kam C Yeung; Fahd Al-Mulla; Eugene Chin; Devasis Chatterjee
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

10.  RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.

Authors:  Sam Cross-Knorr; Shaolei Lu; Kimberly Perez; Sara Guevara; Kate Brilliant; Claudio Pisano; Peter J Quesenberry; Murray B Resnick; Devasis Chatterjee
Journal:  BMC Cancer       Date:  2013-10-08       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.